PP2A activity was measured in peripheral blood
neutrophils from A1AT-deficient (PiZZ) and healthy (PiMM)
individuals and in alveolar macrophages from normal (60 mg/kg)
and high-dose (120 mg/kg) A1AT-treated PiZZ subjects. PP2A
activation was assessed in human neutrophils, airway epithelial cells,
and peripheral blood monocytes treated with plasma purified A1AT
protein. Similarly, lung PP2A activity was measured in mice
administered intranasal A1AT.